ARTICLE | Company News
3-Dimensional, Boehringer Ingelheim Pharmaceuticals Inc. deal
March 13, 2000 8:00 AM UTC
3-D will use its DirectedDiversity combinatorial chemistry to identify compounds active against targets selected by Boehringer Ingelheim. 3-D will receive an upfront technology access fee, R&D funding, milestones and royalties. Boehringer Ingelheim is responsible for development of selected compounds. ...